Etretinate (Tigason) hepatitis in 2 patients.
A histologically confirmed, clinically inapparent and reversible hepatitis occurred in 2 patients (1 psoriasis, 1 basal cell nevus syndrome) within the first months after introduction of etretinate therapy. Causes of hepatitis other than etretinate were not found. Reintroduction of etretinate resulted in reactivation and/or persistence of the hepatitis in both patients. These data strongly suggest that the hepatitis in both patients was caused by etretinate. Later the basal cell nevus syndrome patient was given 13-cis-retinoic acid, which caused no liver test disturbances during a follow-up period of 6 months.
D000368:Aged; D001478:Basal Cell Nevus Syndrome / Q000188:drug therapy*; D001706:Biopsy; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D005050:Etretinate / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D014212:Tretinoin / Q000627:therapeutic use
D014212:Tretinoin; D005050:Etretinate